Feb, 2024. the Category 1 innovative product Ganagliflozin Proline Tablets of Jilin Huisheng Bio-Pharmaceutical Co. Ltd (Huisheng Pharm)was approved for marketing by China NMPA.
Ganagliflozin Proline Tablets is a sodium glucose co-transporter 2 (SGLT2) inhibitor that inhibits SGLT2, reduces the re-absorption of filtered glucose, lowers the renal threshold of glucose, and thus increases urine glucose excretion. This is the second independently developed SGLT-2 inhibitor innovative drug to be approved for marketing in China, marking Huisheng’s breakthrough progress in the research and development of innovative drugs in the field of diabetes treatment.
Ganagliflozin Proline Tablets is indicated to improve the blood sugar control for adult patients with type 2 diabetes by singe use or combined use with metformin hydrochloride. The marketing of this drug provides new treatment options for adult patients with type 2 diabetes.
About Jilin Huisheng Bio-Pharmaceutical Co. Ltd
In May 2019, Huisheng Biopharmaceutical Co., Ltd. was born under the strategic transformation of Sihuan Pharmaceutical. It focuses on the treatment of diabetes and complications and is a biopharmaceutical company with a complete product pipeline for diabetes and complications. The products cover the latest mechanism of the Class 1.1 innovative drug inhibitor gagliflozin, the full range of insulin represented by the fourth generation insulin degludec, GLP-1 analogues represented by semaglutide, and more than 40 various mechanisms. A variety of medications for hypoglycemic and complications such as diabetic retina and neuropathy.
